Beyond Hormone Therapy: Signs Of Life In Pipeline For Menopausal Women
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Conditions associated with menopause represent a huge market, yet the R&D pipeline has long been slim, despite the well-known drawbacks of marketed hormone replacement therapies. But new approaches with a tissue-selective estrogenic effect are emerging: Shionogi’s Osphena for menopause-related sexual dysfunction broke the long drought in NME approvals, and Pfizer’s broad NDA for bazedoxifene/conjugated estrogens is under review. Emerging companies like EndoCeutics are exploring new hormonal approaches.
You may also be interested in...
Keeping Track: FDA Approves First Rx DHEA, Receives Applications For Midostaurin, Gesulkumab, Biosimilar Avastin
The latest drug development news and highlights from our FDA Performance Tracker.
Pfizer’s Duavee Approved For Hot Flashes, Osteoporosis Prevention
FDA cleared the single pill combining conjugated estrogens with bazedoxifene, a novel selective estrogen receptor modulator, for two indications but issued a “complete response” letter for use in vulvar and vaginal atrophy.
Noven Gains Brisdelle Approval Over Advisory Committee Concerns
Low dose version of paroxetine indicated for hot flashes even though advisory committee members questioned trials’ placebo effect.